Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitrous Oxide in Major Depressive Disorder
NCT05357040Phase 2Withdrawn
- Sponsor
- University of Chicago
- Start
- Jun 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of nitrous oxide in major depressive disorder (MDD), treatment-resistant depression (TRD), sponsored by University of Chicago. Planned start Jun 2021; status: withdrawn.
02
Drugs
nitrous oxide
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05357040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357040.